AstraZeneca (AZN.L) on Tuesday received $23.7 million in funding from a US government agency to advance the development of antibody-based COVID-19 treatments as the British drugmaker ramps up efforts beyond its potential vaccine to combat the pandemic.

The funding from the BARDA is part of a collaboration deal between AstraZeneca, BARDA and DARPA to back the drugmaker's development of a monoclonal antibody treatment against the new coronavirus. Source: Reuters 9/6/2020